期刊
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
卷 89, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.jddst.2023.104970
关键词
Brain; Blood-brain barrier; Dementia; Mesoporous silica nanoparticles; Neurological disorder
Neurological disorders pose an emerging threat to public health, and traditional therapy is unable to fully cure these disorders due to poor blood-brain barrier permeability. Scientists have focused on developing novel drug delivery carriers, such as mesoporous silica nanoparticles, to improve drug delivery to the brain. These nanoparticles have unique properties that make them suitable for delivering drugs to the brain and have been extensively studied for treating neurological disorders.
In the current scenario neurological disorders are an emerging threat to public health. These disorders affect neuronal functions and produce symptoms such as cognitive dysfunction, poor coordination, paralysis, seizures, muscle weakness, and pain. However, traditional therapy is incapable of completely curing the disorders due to the poor blood-brain barrier (BBB) permeability of the administered therapeutics. In recent years, scientists have laid a strong focus on leading-edge novel drug delivery carriers to improve the delivery of drugs to the brain. Novel drug delivery carriers aim to deliver active moieties at the site of action to avoid any undesirable side effects. In this task, mesoporous silica nanoparticles (MSNs) are well capable due to unique structural and physicochemical properties such as high surface area, tunable pore size, surface conjugation, and biocompatibility. The MSNs protect the encapsulated drug against premature metabolism or degradation and allow sitespecific controlled drug release and stability. Due to its significant advantages, it has been greatly explored to deliver brain therapeutics in treating neurological disorders in the past few years. Thus, an attempt has been made in this review to briefly discuss the barriers associated with brain drug delivery and crucial formulation features for effective delivery to the brain. Further, the key potential of MSNs as a novel carrier in treating neurological disorders such as Alzheimer's disease, brain tumor, Parkinson's disease, epilepsy, depression, intracerebral hemorrhage, viral encephalitis, nerve agent toxicity, and, multiple sclerosis are highlighted in this compilation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据